Company / SG&A Expense
NEPHROS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$9.0M
FY2025
5-year range
$7.2M / $9.0M
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $8M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +6.8%.
Increased from $8M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 1.0% year-over-year.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -5.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.0M | +1.0% |
| FY2024 | $8.9M | +17.4% |
| FY2023 | $7.6M | +0.0% |
| FY2022 | $7.6M | +5.5% |
| FY2021 | $7.2M | +11.3% |
| FY2020 | $6.5M | +5.7% |
| FY2019 | $6.1M | +35.5% |
| FY2018 | $4.5M | +58.3% |
| FY2017 | $2.9M | +0.0% |
| FY2016 | $2.9M | -17.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026